Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban

• Verfasst von: Harenberg, Job [VerfasserIn]
• Verfasst von: Jörg, Ingrid [VerfasserIn]
• Verfasst von: Fenyvesi, Tivadar [VerfasserIn]
• Verfasst von: Piazolo, Lukas [VerfasserIn]
• Titel: Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban
• Verf.angabe: Harenberg Job, Jörg Ingrid, Fenyvesi Tivadar, Piazolo Lukas
• Jahr: 2005
• Umfang: 5 S.
• Fussnoten: Gesehen am 20.04.2022
• Titel Quelle: Enthalten in: Journal of thrombosis and thrombolysis
• Ort Quelle: Dordrecht [u.a.] : Springer Science + Business Media B.V, 1994
• Jahr Quelle: 2005
• Band/Heft Quelle: 19(2005), 1, Seite 65-69
• ISSN Quelle: 1573-742X
• DOI: doi:10.1007/s11239-005-0942-4
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anticoagulation
• Sach-SW: argatroban
• Sach-SW: heparin-induced thrombocytopenia
• Sach-SW: lepirudin
• K10plus-PPN: 1799837750

Abstract

Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thrombin inhibitor argatroban does not induce immunoglobulins reacting towards lepirudin in patients with anti-lepirudin antibodies in the history and that titration of the anticoagulation may be easier with argatroban.